Frederick B Stehman

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi request reprint Carcinoma of the vulva
    Frederick B Stehman
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Obstet Gynecol 107:719-33. 2006
  2. pmc Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study
    Frederick B Stehman
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 127:495-501. 2012
  3. pmc Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Am J Obstet Gynecol 197:503.e1-6. 2007
  4. doi request reprint Node count and groin recurrence in early vulvar cancer: A Gynecologic Oncology Group study
    Frederick B Stehman
    Gynecologic Oncology, The Clarence E Ehrlich Chair Emeritus, Department of Obstetrics and Gynecology, Indiana University School of Medicine, 535 Barnhill, 433, Indianapolis, IN 46202, USA
    Gynecol Oncol 113:52-6. 2009
  5. ncbi request reprint Innovations in the treatment of invasive cervical cancer
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5274, USA
    Cancer 98:2052-63. 2003
  6. doi request reprint Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 121:542-5. 2011
  7. pmc Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized T
    Peter G Rose
    Peter G Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY Charles W Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE Frederick B Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA Gillian M Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada and Paul A DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI
    J Clin Oncol 33:2136-42. 2015
  8. pmc Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation
    Peter G Rose
    Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH 44195, United States Electronic address
    Gynecol Oncol 135:208-12. 2014
  9. ncbi request reprint Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy
    Jeanne M Schilder
    Department of Ob Gyn, Division of Gynecologic Oncology, Indiana University Medical Center, 535 Barnhill Drive, Rm 436, Indianapolis, IN 46202 6294, USA
    Gynecol Oncol 87:1-7. 2002
  10. doi request reprint Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer
    Lisa M Hess
    Indiana University School of Medicine, Department of Obstetrics and Gynecology, Indianapolis, IN 46202, USA
    Gynecol Oncol 127:564-8. 2012

Detail Information

Publications17

  1. ncbi request reprint Carcinoma of the vulva
    Frederick B Stehman
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Obstet Gynecol 107:719-33. 2006
    ..Adequately powered trials aimed at further reducing morbidity without compromising survival are underway...
  2. pmc Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study
    Frederick B Stehman
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 127:495-501. 2012
    ..We assessed whether G-CSF or ESA were associated with progression or death in patients with ovarian cancer...
  3. pmc Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Am J Obstet Gynecol 197:503.e1-6. 2007
    ....
  4. doi request reprint Node count and groin recurrence in early vulvar cancer: A Gynecologic Oncology Group study
    Frederick B Stehman
    Gynecologic Oncology, The Clarence E Ehrlich Chair Emeritus, Department of Obstetrics and Gynecology, Indiana University School of Medicine, 535 Barnhill, 433, Indianapolis, IN 46202, USA
    Gynecol Oncol 113:52-6. 2009
    ..To determine if low node count from superficial groin dissection correlated with first recurrence in the groin for patients with early vulvar cancer...
  5. ncbi request reprint Innovations in the treatment of invasive cervical cancer
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5274, USA
    Cancer 98:2052-63. 2003
    ..Research advances in both diagnosis and treatment are expected to improve therapy and outcomes...
  6. doi request reprint Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 121:542-5. 2011
    ..To evaluate the outcome of stage IVA cervical cancer treated with radiation and concurrent cisplatin-based chemotherapy...
  7. pmc Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized T
    Peter G Rose
    Peter G Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY Charles W Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE Frederick B Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA Gillian M Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada and Paul A DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI
    J Clin Oncol 33:2136-42. 2015
    ..To evaluate the prognostic factors in locally advanced cervical cancer limited to the pelvis and develop nomograms for 2-year progression-free survival (PFS), 5-year overall survival (OS), and pelvic recurrence...
  8. pmc Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation
    Peter G Rose
    Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH 44195, United States Electronic address
    Gynecol Oncol 135:208-12. 2014
    ..The current study sought to evaluate impact of adeno- and adenosquamous histology in the randomized trials of primary cisplatin-based chemoradiation for locally advanced cervical cancer...
  9. ncbi request reprint Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy
    Jeanne M Schilder
    Department of Ob Gyn, Division of Gynecologic Oncology, Indiana University Medical Center, 535 Barnhill Drive, Rm 436, Indianapolis, IN 46202 6294, USA
    Gynecol Oncol 87:1-7. 2002
    ..The purpose of this study was to determine the recurrence rate, survival, and pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer treated with unilateral adnexectomy...
  10. doi request reprint Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer
    Lisa M Hess
    Indiana University School of Medicine, Department of Obstetrics and Gynecology, Indianapolis, IN 46202, USA
    Gynecol Oncol 127:564-8. 2012
    ..The goal of this study was to describe the various pathways and to identify an optimal path to accurate diagnosis...
  11. doi request reprint State of the science in ovarian cancer quality of life research: a systematic review
    Lisa M Hess
    Department of Public Health, Indiana University School of Medicine, Indianapolis 46202, USA
    Int J Gynecol Cancer 22:1273-80. 2012
    ..Quality-of-life outcomes are important in ovarian cancer, which has not yet benefitted from improved survival outcomes as have other diseases. This study was designed to systematically assess and summarize HRQOL in ovarian cancer...
  12. pmc Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer
    Qingchun Cai
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    FASEB J 26:3306-20. 2012
    ..PLA(2) activity was found in conditioned media from both EOC cells and macrophages. Collectively, our work implies that PLA(2) activity is a potential marker and therapeutic target in EOC...
  13. ncbi request reprint Stage Ia-IIa cancer of the cervix
    Jeanne M Schilder
    Indiana University School of Medicine, 535 Barnhill Drive, Room 436, Indianapolis, IN 46202 5274, USA
    Cancer J 9:395-403. 2003
    ..A thorough discussion between the physician and patient is necessary to determine the optimal management for each individual. This review discusses the major factors that influence physician and patient management choices...
  14. ncbi request reprint "What's in a name? That which we call a rose, by any other name."
    Frederick B Stehman
    Obstet Gynecol 100:1146-7. 2002
  15. ncbi request reprint Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group
    Henry M Keys
    Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA
    Gynecol Oncol 89:343-53. 2003
    ..To evaluate, in a randomized clinical trial, the role of adjuvant hysterectomy after standardized radiation in improving progression-free survival and survival for patients with "bulky" stage IB cervical cancer...
  16. ncbi request reprint Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group
    Mahesh A Varia
    Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    J Clin Oncol 21:2849-55. 2003
    ....
  17. ncbi request reprint A thousand several tongues
    Frederick B Stehman
    Gynecol Oncol 94:247-8. 2004